In-vitro and in-vivo susceptibility of Aspergillus fumigatus to a novel conjugated styryl ketone

Elias Kurian Manavathu, Jonathan R. Dimmock, Sarvesh C. Vashishtha, Jessica Cutright, Pranatharthi H. Chandrasekar

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

We investigated the in-vitro and in-vivo susceptibility of Aspergillus fumigatus to the novel conjugated styryl ketone NC1175 and the results were compared with those obtained for amphotericin B and itraconazole. All 20 clinical isolates of A. fumigatus examined were susceptible to NC1175 (MIC = 5.54 ± 2.48 mg/L; range 2.92-11.68 mg/L), and the minimum lethal concentration (MLC) was only twice the MIC, suggesting that NC1175 is fungicidal. The mean MIC values of amphotericin B (1.22 ± 0.58 mg/L; range 0.5-4 mg/L) and itraconazole (0.37 ± 0.11 mg/L; range 0.125-0.5 mg/L) were approximately nine- and 22-fold, respectively, lower than that of NC1175. Both amphotericin B-resistant (n = 18) and itraconazole-resistant (n = 28) isolates of A. fumigatus were as susceptible to NC1175 as amphotericin B-, and itraconazole-susceptible isolates. Kill curve experiments revealed that NC1175 at 23.35 mg/L (approximately four times the MIC) killed ≥ 99% of conidia within 24 h of exposure to the drug. The in-vivo susceptibility of A. fumigatus to NC1175 was investigated using a murine pulmonary aspergillosis model. Treatment of infected mice with amphotericin B or NC1175 did not result in significant improvement of the mean survival (amphotericin B, 7.05 ± 0.07 days; NC1175, 6.65 ± 1.25 days) of the animals compared with that of the placebo group (7.21 ± 1.20 days). However, semiquantitative organ culture revealed that clearance of A. fumigatus occurred in 16.6%, 50% and 66.6% of the mice treated with placebo, NC1175 and amphotericin B, respectively (P value for the control and the treated groups < 0.01). These results suggest that NC1175 has in-vivo and in-vitro activity against A. fumigatus and can be used as a prototypic molecule for further development as an antifungal agent.

Original languageEnglish (US)
Pages (from-to)585-590
Number of pages6
JournalJournal of Antimicrobial Chemotherapy
Volume42
Issue number5
DOIs
StatePublished - Nov 1 1998

Fingerprint

Aspergillus fumigatus
Ketones
Amphotericin B
Itraconazole
NC 1175
In Vitro Techniques
Placebos
Pulmonary Aspergillosis
Fungal Spores
Antifungal Agents
Organ Culture Techniques

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Manavathu, E. K., Dimmock, J. R., Vashishtha, S. C., Cutright, J., & Chandrasekar, P. H. (1998). In-vitro and in-vivo susceptibility of Aspergillus fumigatus to a novel conjugated styryl ketone. Journal of Antimicrobial Chemotherapy, 42(5), 585-590. https://doi.org/10.1093/jac/42.5.585

In-vitro and in-vivo susceptibility of Aspergillus fumigatus to a novel conjugated styryl ketone. / Manavathu, Elias Kurian; Dimmock, Jonathan R.; Vashishtha, Sarvesh C.; Cutright, Jessica; Chandrasekar, Pranatharthi H.

In: Journal of Antimicrobial Chemotherapy, Vol. 42, No. 5, 01.11.1998, p. 585-590.

Research output: Contribution to journalArticle

Manavathu, EK, Dimmock, JR, Vashishtha, SC, Cutright, J & Chandrasekar, PH 1998, 'In-vitro and in-vivo susceptibility of Aspergillus fumigatus to a novel conjugated styryl ketone', Journal of Antimicrobial Chemotherapy, vol. 42, no. 5, pp. 585-590. https://doi.org/10.1093/jac/42.5.585
Manavathu, Elias Kurian ; Dimmock, Jonathan R. ; Vashishtha, Sarvesh C. ; Cutright, Jessica ; Chandrasekar, Pranatharthi H. / In-vitro and in-vivo susceptibility of Aspergillus fumigatus to a novel conjugated styryl ketone. In: Journal of Antimicrobial Chemotherapy. 1998 ; Vol. 42, No. 5. pp. 585-590.
@article{c5629eee15df4b11856f2b4a96df2731,
title = "In-vitro and in-vivo susceptibility of Aspergillus fumigatus to a novel conjugated styryl ketone",
abstract = "We investigated the in-vitro and in-vivo susceptibility of Aspergillus fumigatus to the novel conjugated styryl ketone NC1175 and the results were compared with those obtained for amphotericin B and itraconazole. All 20 clinical isolates of A. fumigatus examined were susceptible to NC1175 (MIC = 5.54 ± 2.48 mg/L; range 2.92-11.68 mg/L), and the minimum lethal concentration (MLC) was only twice the MIC, suggesting that NC1175 is fungicidal. The mean MIC values of amphotericin B (1.22 ± 0.58 mg/L; range 0.5-4 mg/L) and itraconazole (0.37 ± 0.11 mg/L; range 0.125-0.5 mg/L) were approximately nine- and 22-fold, respectively, lower than that of NC1175. Both amphotericin B-resistant (n = 18) and itraconazole-resistant (n = 28) isolates of A. fumigatus were as susceptible to NC1175 as amphotericin B-, and itraconazole-susceptible isolates. Kill curve experiments revealed that NC1175 at 23.35 mg/L (approximately four times the MIC) killed ≥ 99{\%} of conidia within 24 h of exposure to the drug. The in-vivo susceptibility of A. fumigatus to NC1175 was investigated using a murine pulmonary aspergillosis model. Treatment of infected mice with amphotericin B or NC1175 did not result in significant improvement of the mean survival (amphotericin B, 7.05 ± 0.07 days; NC1175, 6.65 ± 1.25 days) of the animals compared with that of the placebo group (7.21 ± 1.20 days). However, semiquantitative organ culture revealed that clearance of A. fumigatus occurred in 16.6{\%}, 50{\%} and 66.6{\%} of the mice treated with placebo, NC1175 and amphotericin B, respectively (P value for the control and the treated groups < 0.01). These results suggest that NC1175 has in-vivo and in-vitro activity against A. fumigatus and can be used as a prototypic molecule for further development as an antifungal agent.",
author = "Manavathu, {Elias Kurian} and Dimmock, {Jonathan R.} and Vashishtha, {Sarvesh C.} and Jessica Cutright and Chandrasekar, {Pranatharthi H.}",
year = "1998",
month = "11",
day = "1",
doi = "10.1093/jac/42.5.585",
language = "English (US)",
volume = "42",
pages = "585--590",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - In-vitro and in-vivo susceptibility of Aspergillus fumigatus to a novel conjugated styryl ketone

AU - Manavathu, Elias Kurian

AU - Dimmock, Jonathan R.

AU - Vashishtha, Sarvesh C.

AU - Cutright, Jessica

AU - Chandrasekar, Pranatharthi H.

PY - 1998/11/1

Y1 - 1998/11/1

N2 - We investigated the in-vitro and in-vivo susceptibility of Aspergillus fumigatus to the novel conjugated styryl ketone NC1175 and the results were compared with those obtained for amphotericin B and itraconazole. All 20 clinical isolates of A. fumigatus examined were susceptible to NC1175 (MIC = 5.54 ± 2.48 mg/L; range 2.92-11.68 mg/L), and the minimum lethal concentration (MLC) was only twice the MIC, suggesting that NC1175 is fungicidal. The mean MIC values of amphotericin B (1.22 ± 0.58 mg/L; range 0.5-4 mg/L) and itraconazole (0.37 ± 0.11 mg/L; range 0.125-0.5 mg/L) were approximately nine- and 22-fold, respectively, lower than that of NC1175. Both amphotericin B-resistant (n = 18) and itraconazole-resistant (n = 28) isolates of A. fumigatus were as susceptible to NC1175 as amphotericin B-, and itraconazole-susceptible isolates. Kill curve experiments revealed that NC1175 at 23.35 mg/L (approximately four times the MIC) killed ≥ 99% of conidia within 24 h of exposure to the drug. The in-vivo susceptibility of A. fumigatus to NC1175 was investigated using a murine pulmonary aspergillosis model. Treatment of infected mice with amphotericin B or NC1175 did not result in significant improvement of the mean survival (amphotericin B, 7.05 ± 0.07 days; NC1175, 6.65 ± 1.25 days) of the animals compared with that of the placebo group (7.21 ± 1.20 days). However, semiquantitative organ culture revealed that clearance of A. fumigatus occurred in 16.6%, 50% and 66.6% of the mice treated with placebo, NC1175 and amphotericin B, respectively (P value for the control and the treated groups < 0.01). These results suggest that NC1175 has in-vivo and in-vitro activity against A. fumigatus and can be used as a prototypic molecule for further development as an antifungal agent.

AB - We investigated the in-vitro and in-vivo susceptibility of Aspergillus fumigatus to the novel conjugated styryl ketone NC1175 and the results were compared with those obtained for amphotericin B and itraconazole. All 20 clinical isolates of A. fumigatus examined were susceptible to NC1175 (MIC = 5.54 ± 2.48 mg/L; range 2.92-11.68 mg/L), and the minimum lethal concentration (MLC) was only twice the MIC, suggesting that NC1175 is fungicidal. The mean MIC values of amphotericin B (1.22 ± 0.58 mg/L; range 0.5-4 mg/L) and itraconazole (0.37 ± 0.11 mg/L; range 0.125-0.5 mg/L) were approximately nine- and 22-fold, respectively, lower than that of NC1175. Both amphotericin B-resistant (n = 18) and itraconazole-resistant (n = 28) isolates of A. fumigatus were as susceptible to NC1175 as amphotericin B-, and itraconazole-susceptible isolates. Kill curve experiments revealed that NC1175 at 23.35 mg/L (approximately four times the MIC) killed ≥ 99% of conidia within 24 h of exposure to the drug. The in-vivo susceptibility of A. fumigatus to NC1175 was investigated using a murine pulmonary aspergillosis model. Treatment of infected mice with amphotericin B or NC1175 did not result in significant improvement of the mean survival (amphotericin B, 7.05 ± 0.07 days; NC1175, 6.65 ± 1.25 days) of the animals compared with that of the placebo group (7.21 ± 1.20 days). However, semiquantitative organ culture revealed that clearance of A. fumigatus occurred in 16.6%, 50% and 66.6% of the mice treated with placebo, NC1175 and amphotericin B, respectively (P value for the control and the treated groups < 0.01). These results suggest that NC1175 has in-vivo and in-vitro activity against A. fumigatus and can be used as a prototypic molecule for further development as an antifungal agent.

UR - http://www.scopus.com/inward/record.url?scp=0031769840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031769840&partnerID=8YFLogxK

U2 - 10.1093/jac/42.5.585

DO - 10.1093/jac/42.5.585

M3 - Article

C2 - 9848441

AN - SCOPUS:0031769840

VL - 42

SP - 585

EP - 590

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 5

ER -